Clinical trials: Rosacea, Papulopustular
Papulopustular Rosacea
A 21 Day Pharmacokinetics Study in Papulopustular Rosacea
The purpose of this study is to characterize the pharmacokinetics of once daily topical gel and confirm that steady state conditions are reached under maximal use conditions following 3 weeks of daily applications.
- Trial name
- NCT02028286
- Testing
- CLS001
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03448939
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Rosacea
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular…
- Trial name
- NCT01308619
- Testing
- Doxycycline
- Where
- 10 sites in United States
- Volunteers
- 170 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea. The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release…
- Trial name
- NCT03864978
- Testing
- Rifaximin delayed release 400 mg tablet
- Where
- 12 sites in Italy
- Volunteers
- 236 people
- Sponsor
- Alfasigma S.p.A.
Papulopustular Rosacea
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular…
- Trial name
- NCT07681271
- Testing
- LOU064
- Where
- 12 sites in United States, Bulgaria and 6 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Papulopustular Rosacea
A Twelve Week Safety and Efficacy Study in Rosacea
The purpose of this study is to evaluate th safety and efficacy of one-daily topical application of CLS001 low, mid and high dose compared to vehicle gel in subjects with papulopustular rosacea.
- Trial name
- NCT01784133
- Testing
- omiganan
- Where
- 17 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Rosacea
Effect of CD07805/47 Gel in Rosacea Flushing
Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of the flush of rosacea.
- Trial name
- NCT02300129
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-1 (NCT05296629)
- Testing
- DFD-29, Doxycycline
- Where
- 27 sites in United States
- Volunteers
- 323 people
- Sponsor
- Journey Medical Corporation
Moderate to Severe Papulopustular Rosacea
Clinical Endpoint Study of Ivermectin 1% Cream
A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin)…
- Trial name
- NCT02840461
- Testing
- Ivermectin Cream, 1%
- Where
- United States
- Volunteers
- 630 people
- Sponsor
- Actavis Inc.
Papulopustular Rosacea
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Study objectives: To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment.
- Trial name
- ATTRACT (NCT01493947)
- Testing
- Ivermectin 1% cream, Metronidazole 0.75% cream
- Where
- 60 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 962 people
- Sponsor
- Galderma R&D
Moderate to Severe Papulopustular Rosacea
Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea
An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.
- Trial name
- NCT03050086
- Testing
- BPX-04 1% minocycline topical gel, BPX-04 2% minocycline topical gel, BPX-04 vehicle topical gel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BioPharmX, Inc.
Papulopustular Rosacea
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
The overall objective of this study is to assess how the use of the drug may shift the skin microbiome and skin biophysical properties.
- Trial name
- NCT05675501
- Testing
- Encapsulated Benzoyl Peroxide Cream
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.
- Trial name
- NCT00617903
- Testing
- Azelaic acid, Vehicle foam
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-2 (NCT05343455)
- Testing
- DFD-29, Doxycycline
- Where
- 24 sites in United States, Germany
- Volunteers
- 330 people
- Sponsor
- Journey Medical Corporation
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.
- Trial name
- NCT02393937
- Testing
- Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%
- Where
- 27 sites in United States
- Volunteers
- 963 people
- Sponsor
- bioRASI, LLC
Papulopustular Rosacea
Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea
This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle.
- Trial name
- PRISM (NCT03667222)
- Testing
- minocycline topical gel, topical gel vehicle
- Where
- 12 sites in United States
- Volunteers
- 207 people
- Sponsor
- BioPharmX, Inc.
Papulopustular Rosacea
Study of TP-04 in Participants With Papulopustular Rosacea
This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR).
- Trial name
- NCT05838170
- Testing
- Lotilaner Gel, 2.0%, Vehicle control gel
- Where
- 5 sites in Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Papulopustular Rosacea
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.
- Trial name
- NCT05150587
- Testing
- Rifaximin
- Where
- 38 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alfasigma S.p.A.
Papulopustular Rosacea
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
- Trial name
- NCT03564145
- Testing
- S5G4T-1
- Where
- United States
- Volunteers
- 547 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01494467
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 688 people
- Sponsor
- Galderma R&D